Switch theme
Sign up to access all valuation multiples
Isofol Medical AB is a pharmaceutical company. It is a manufacturer of folate-based therapies. The company's drug candidate Modufolin enhances the effect of the current chemotherapy treatment for patients treated for colorectal cancer. Its products are used to increase efficacy and reduce the side effects of antimetabolite cancer treatment.
2008
4
Last FY Revenue n/a
Last FY EBITDA -$4.5M
$2.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Isofol Medical achieved revenue of n/a and an EBITDA of -$4.5M.
Isofol Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Isofol Medical valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | XXX | n/a | XXX | XXX | XXX |
| EBITDA | XXX | -$4.5M | XXX | XXX | XXX |
| EBITDA Margin | XXX | n/a | XXX | XXX | XXX |
| EBIT | XXX | -$4.9M | XXX | XXX | XXX |
| EBIT Margin | XXX | n/a | XXX | XXX | XXX |
| Net Profit | XXX | -$4.5M | XXX | XXX | XXX |
| Net Margin | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Isofol Medical's stock price is SEK 1 (or $0).
Isofol Medical has current market cap of SEK 168M (or $17.3M), and EV of SEK 23.8M (or $2.4M).
See Isofol Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.4M | $17.3M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Isofol Medical has market cap of $17.3M and EV of $2.4M.
Isofol Medical's trades at 32.9x EV/Revenue multiple, and -0.5x EV/EBITDA.
Equity research analysts estimate Isofol Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Isofol Medical's P/E ratio is not available.
See valuation multiples for Isofol Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $17.3M | XXX | $17.3M | XXX | XXX | XXX |
| EV (current) | $2.4M | XXX | $2.4M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 32.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -0.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -3.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIsofol Medical's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.
Isofol Medical's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Isofol Medical's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Isofol Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Isofol Medical acquired XXX companies to date.
Last acquisition by Isofol Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . Isofol Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Isofol Medical founded? | Isofol Medical was founded in 2008. |
| Where is Isofol Medical headquartered? | Isofol Medical is headquartered in Sweden. |
| How many employees does Isofol Medical have? | As of today, Isofol Medical has 4 employees. |
| Who is the CEO of Isofol Medical? | Isofol Medical's CEO is Mr. Petter Segelman Lindqvist. |
| Is Isofol Medical publicy listed? | Yes, Isofol Medical is a public company listed on STO. |
| What is the stock symbol of Isofol Medical? | Isofol Medical trades under ISOFOL ticker. |
| When did Isofol Medical go public? | Isofol Medical went public in 2017. |
| Who are competitors of Isofol Medical? | Similar companies to Isofol Medical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Isofol Medical? | Isofol Medical's current market cap is $17.3M |
| Is Isofol Medical profitable? | Yes, Isofol Medical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
